Polyclonal Antibody to Cylindromatosis (CYLD) Homo sapiens (Human) Polyclonal antibody

CDMT; CYLD1; CYLDI; EAC; USPL2; Turban Tumor Syndrome; Ubiquitin Carboxyl-Terminal Hydrolase CYLD; Ubiquitin Specific Peptidase Like 2; Deubiquitinating enzyme CYLD

  • Polyclonal Antibody to Cylindromatosis (CYLD) Packages (Simulation)
  • Polyclonal Antibody to Cylindromatosis (CYLD) Packages (Simulation)
  • Polyclonal Antibody to Cylindromatosis (CYLD) Figure. DAB staining on IHC-P; Samples: Human Liver Cancer Tissue.
  • Polyclonal Antibody to Cylindromatosis (CYLD) Figure. DAB staining on IHC-P; Samples: Human Brain Tissue.
  • Polyclonal Antibody to Cylindromatosis (CYLD) Figure. DAB staining on IHC-P; Samples: Human Prostate Gland Cancer Tissue.
  • Polyclonal Antibody to Cylindromatosis (CYLD) Figure. DAB staining on IHC-P; Samples: Human Glioma Tissue.
  • PAC423Hu01.jpg Figure. Western Blot; Sample: Recombinant CYLD, Human.
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

SPECIFITY

The antibody is a rabbit polyclonal antibody raised against CYLD. It has been selected for its ability to recognize CYLD in immunohistochemical staining and western blotting.

USAGE

Western blotting: 1-5ug/ml
Immunocytochemistry in formalin fixed cells: 5-20ug/ml
Immunohistochemistry in formalin fixed frozen section: 5-20ug/ml
Immunohistochemistry in paraffin section: 5-20ug/ml
Enzyme-linked Immunosorbent Assay: 0.05-2ug/ml
Optimal working dilutions must be determined by end user.

STORAGE

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for one year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Recommend products